Food supplement lozenges Maxisal for dry mouth launched: Amarillo Bio

Maxisal, a dietary supplement to enhance saliva and help relieve dry mouth, has been launched.

Maxisal improves the production of saliva, unstimulated whole saliva, in many people experiencing dryness of the mouth, clinical data indicate.

As of now, temporary relief from dry mouth could only be achieved while the candy or chewing gum was in the mouth.

People with this condition seek relief by increasing fluid intake, chewing sugarless gum or by sucking on sugarless lozenges.

This often makes nighttime relief difficult.

Maxisal has been shown in scientific human clinical studies to help alleviate the oral discomfort due to dry mouth and provide long-term relief.

Occasional dry mouth is associated with aging. Autoimmune diseases such as Sjögren’s syndrome, radiations and certain medications also cause dry mouth.

There are over 400 medications, including some oncology drugs, that cause dry mouth as a severe side effect.

By taking Maxisal, cancer patients may be able to relieve at least one of the side effects of cancer therapy.

With Maxisal, relief of dry mouth was seen after 6 weeks of daily treatment.

It is recommended that Maxisal be taken at least three times per day for at least 6 weeks to experience maximum benefit.

Maxisal was first offered for sale after clinical studies in subjects with Sjogren’s syndrome (characterized by dry eyes and dry mouth) reported that the ingredient in Maxisal significantly improved mouth comfort and decreased mouth and throat dryness.

In two studies involving 119 subjects, Maxisal lozenges administered three times daily for 12 or 24 weeks improved salivary output and decreased complaints of dry mouth, throat and eyes.

In a third study involving 100 subjects, Maxisal lozenges administered three times daily for 24 weeks improved salivary output and decreased complaints of dry mouth, throat and eyes.

Side effects were minimal, and treatment was without significant adverse events.

This safe and simple intervention provides clinical benefit to individuals with distressing dry mouth symptoms, according to the developer of Maxisal, Amarillo Biosciences.

“Based on the favorable reception Maxisal has met in the US, which we attribute to the product’s clinical and safety benefits, as well as reasonable cost– we fully expect that it will be successful in Germany,” said Dr Joseph Cummins, president and CEO, Amarillo Biosciences.

A user of Maxisal should not expect instant relief as chronic problems take time to influence, alerted Amarillos.

Amarillos has also developed a dietary ingredient for natural food distributors to market as a dietary supplement. The ingredient is derived from animals in the feed yards of the Texas Panhandle.

“After more than 30 years of experience testing cytokines, in animals and man, we have developed a novel dietary ingredient derived from ruminant animals,” said Dr Joseph Cummins.

Amarillo Biosciences, is a US biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6 per cent of Amarillo Biosciences shares and has provided over US$ 18 million in loans, grants and equity investments.